Risk sharing deals in drug development often involve a Big Pharma company and a small, research-intensive biotech. Typically, the larger partner pays for rights to a promising asset on the expectation that its investment will pay off years later when the compound becomes a marketed pharmaceutical. Very often the larger company is cash rich, while the smaller one is cash poor but rich in intellectual property.
